Report
Benefit assessment of bisphosphonates, teriparatide and denosumab for the treatment of postmenopausal osteoporosis
Report documents
-
Extract of the final report
Benefit assessment of bisphosphonates, teriparatide and denosumab for the treatment of postmenopausal osteoporosis
-
Final report
Benefit assessment of bisphosphonates, teriparatide and denosumab for the treatment of postmenopausal osteoporosis
-
Documentation of comments on the preliminary report
Benefit assessment of bisphosphonates, teriparatide and denosumab for the treatment of postmenopausal osteoporosis
-
Preliminary report
Benefit assessment of bisphosphonates, teriparatide and denosumab for the treatment of postmenopausal osteoporosis
-
Documentation of comments on the report plan
Benefit assessment of bisphosphonates, teriparatide and denosumab for the treatment of postmenopausal osteoporosis
-
Report plan
Benefit assessment of bisphosphonates, teriparatide and denosumab for the treatment of postmenopausal osteoporosis
Press releases
Osteoporosis after the menopause: fewer vertebral fractures with teriparatide than with risedronate
IQWiG's final report on the comparative benefit assessment of bisphosphonates, teriparatide and denosumab now available in English. No change in results between the preliminary and final report.
Project details
- Project no.
- A19-10
- Commission
- Commission awarded on 30.01.2019 by the Federal Joint Committee (GBA).
- Report type
- Report
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Muscles, bones and joints